NCT02058212

Brief Summary

ROS plays an essential role in the pathogenesis of many reproductive processes. High follicular fluid ROS levels are associated with negative IVF outcomes. is plasma level of reactive oxygen species is affected by antioxidant treatment in endometriotic women?

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
50

participants targeted

Target at P25-P50 for phase_2

Timeline
Completed

Started Mar 2013

Shorter than P25 for phase_2

Geographic Reach
1 country

3 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2013

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2013

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2013

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

February 5, 2014

Completed
5 days until next milestone

First Posted

Study publicly available on registry

February 10, 2014

Completed
Last Updated

February 10, 2014

Status Verified

February 1, 2014

Enrollment Period

7 months

First QC Date

February 5, 2014

Last Update Submit

February 7, 2014

Conditions

Keywords

ICSIantioxidantsROSendometriosis

Outcome Measures

Primary Outcomes (1)

  • plasma reactive oxygen species affection by antioxidant treatment

    measure before and 3months after antioxidant treatment

    3 months

Secondary Outcomes (1)

  • clinical pregnancy rate

    2 months

Study Arms (2)

no antioxidant , ROS , pregnancy outcome

PLACEBO COMPARATOR

no anti oxidant in the form of ascorbate 1000mg, vitamin E 400, zinc and selenium) will be given to endometriotic women undergoing IVF

Drug: ascorbate 1000mg, vitamin E 400, zinc and selenium

antioxidant , ROS , pregnancy outcome

ACTIVE COMPARATOR

anti oxidant in the form of ascorbate 1000mg, vitamin E 400, zinc and selenium)

Drug: ascorbate 1000mg, vitamin E 400, zinc and selenium

Interventions

anti oxidant in the form of ascorbate 1000mg, vitamin E 400, zinc and selenium) are given to half patients only before IVF , plasma level of ROS are detected before and on day of oocyte retrieval then correlated to pregnancy outcome

antioxidant , ROS , pregnancy outcomeno antioxidant , ROS , pregnancy outcome

Eligibility Criteria

Age20 Years - 40 Years
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • patients with endometriosis

You may not qualify if:

  • patients with no endometriosis , not suitable for ICSI-

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (3)

egyption centre for IVF

Maadi, 11451, Egypt

Location

Unknown Facility

Maadi, 11451, Egypt

Location

Unknown Facility

Maadi, 1, Egypt

Location

MeSH Terms

Conditions

Endometriosis

Interventions

ZincSelenium

Condition Hierarchy (Ancestors)

Genital Diseases, FemaleFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesGenital Diseases

Intervention Hierarchy (Ancestors)

Metals, HeavyElementsInorganic ChemicalsTransition ElementsMetalsChalcogensMinerals

Study Officials

  • olfat nouh riad, MD

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
assisstant professor

Study Record Dates

First Submitted

February 5, 2014

First Posted

February 10, 2014

Study Start

March 1, 2013

Primary Completion

October 1, 2013

Study Completion

December 1, 2013

Last Updated

February 10, 2014

Record last verified: 2014-02

Locations